$695 | Single User
$1395 | Global License

Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 08 Jul 2014 | 135 | In Stock
Related Topics: FDA

Introduction

Scope



Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tracked since FDA approval last December – but how are physicians based in the EU5 utilising the product?


FirstWord is polling gastroenterologists/hepatologists and infectious disease specialists based in France, Germany, Italy, Spain and the UK this week to ascertain how easily physicians are able to access Sovaldi and in what patients/treatment regimens they are most frequently using Gilead's product.


While both strong uptake for Sovaldi and vocal opposition from payers has shaped the launch narrative for this drug in the US (see also - Physician Views Poll Results: Gilead's all-oral hepatitis C combo launch poised to better Sovaldi US debut despite payer scrutiny) its European performance has been less focused on.


The potential significance of the European market was highlighted late last week when Bristol-Myers Squibb's daclatasvir was recommended for approval in the region. Due to become available some months ahead of Gilead's own Sovaldi/ledipasvir combination, Merck's product is likely to benefit from some uptake in combination with Sovaldi, argue analysts at Bloomberg Industries.


Whether this is sustainable once Gilead's fixed-dose combination, or AbbVie's all-oral offering, launches is conjecture. However, more nuanced access challenges in Europe are likely to shape the competitive environment for next-generation hepatitis C therapies over the next few years.


Puchase Reasons


With this in mind, FirstWord's latest Physician Views poll looks to provide greater insight into the launch of Sovaldi to date in the EU5. Specifically we are asking physicians...


  • How they describe their access to Sovaldi to date?

  • What percentage of total hepatitis C patients they have treated in 2014 have received Sovaldi in some capacity?

  • What patient genotype they are treating most frequently with Sovaldi...

  • ...and for this patient genotype in what regimen they are using Sovaldi most frequently?

  • What percentage of hepatitis C patients (irrespective of genotype) they are currently warehousing for treatment with an all-oral and interferon/ribavirin- sparing regimen?
  • Table of Contents
    for Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    135 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...